Given Imaging Announces Further Insurance Reimbursement For Capsule Endoscopy

17 Million Additional Americans Covered for Suspected Crohn's Disease

Yoqneam, Israel - March 22, 2004 - Given Imaging (NASDAQ: GIVN) announced today that Aetna, Excellus Blue Cross Blue Shield, and Blue Cross Blue Shield of Minnesota have expanded their reimbursement policies for Capsule Endoscopy to include the initial diagnosis of suspected Crohn's disease following inconclusive conventional tests such as small-bowel follow-through and upper and lower endoscopy. In addition, John Deere Health Plan, Inc. has issued a reimbursement policy for Capsule Endoscopy as a first line tool with persistent symptoms following negative upper and lower endoscopy.

“We are pleased that additional insurance companies are recognizing the clinical utility of using Capsule Endoscopy in the initial diagnosis of patients with Crohn's disease,” said Gavriel D. Meron, President and CEO of Given Imaging. “Today's news is of great importance to individuals who suffer from abdominal symptoms that can not be explained with customary diagnostic tools.”

Aetna is a leading provider of health insurance and has 13 million members nationwide. Aetna has provided coverage for Capsule Endoscopy since April 2003 for diagnosing obscure gastrointestinal bleeding, and has now amended its policy to also cover the initial diagnosis of suspected Crohn's disease.

Excellus Blue Cross Blue Shield provides health insurance to more than 2 million individuals in upstate New York, and Blue Cross Blue Shield of Minnesota has more than 2 million members. With these new policies, a total of seven Blue Cross Blue Shield carriers with 27.3 million beneficiaries have adopted the Blue Cross and Blue Shield Association's Medical Advisory Panel determination in November 2003 that Capsule Endoscopy meets the criteria of the association's Technology Evaluation Center (TEC) for initially diagnosing patients with suspected Crohn's disease, following negative conventional diagnostic tests such as barium follow-through and upper and lower endoscopy.

John Deer Health Plan has approximately 530,000 members and serves individuals in Iowa, Illinois, Tennessee and Virginia.

With this announcement, the total U.S. population with reimbursable access to Capsule Endoscopy for indications other than bleeding is approximately 50 million. More than 150 million Americans currently have reimbursable access to Capsule Endoscopy.

About Given Imaging
Imaging Given Imaging develops, produces and markets the Given® Diagnostic System featuring the M2A® Capsule Endoscope, the only method for direct visualization of the entire small intestine that is naturally ingested. The system uses a disposable miniature video camera contained in a capsule which is ingested by the patient. The M2A® Capsule passes naturally through the digestive tract, transmitting high quality color images, without interfering with the patient's normal activities. The system received clearance from the FDA in August 2001 and received permission to affix the CE mark in May 2001. Distribution channels for the system have been established in more than 50 countries worldwide. More than 80,000 capsules have been used in clinical practice. Thousands of patients around the world have benefited from the M2A® Capsule which has been used to diagnose a range of diseases of the small intestine including Crohn's Disease, Celiac disease and other malabsorption disorders, benign and malignant tumors, vascular disorders and medication-related small bowel injury, as well as a range of pediatric small bowel disorders. For more information, visit www.givenimaging.com.

This press release contains forward-looking statements about Given Imaging, including projections about our business, our future revenues, and our future profitability, within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. For example, statements in the future tense, words such as "anticipates," "estimates," "expects," "intends," "plans," "believes," and words and terms of similar substance used in connection with any discussion of future operating or financial performance identify such forward-looking statements. Those forward-looking statements are not guarantees of future performance and actual results could differ materially from our current expectations as a result of numerous factors, including but not limited to the following: changes in regulatory environment, our success in implementing our sales, marketing and manufacturing plan, protection and validity of patents and other intellectual property rights, the impact of currency exchange rates, the effect of competition by other companies, the outcome of future litigation, the reimbursement policies for our product from healthcare payors, quarterly variations in operating results, the possibility of armed conflict or civil or military unrest in Israel and other risks disclosed in our filings with the U.S. Securities Exchange Commission.

19.May'04